Ixabepilone Administered as an Enteric Coated Formulation.

Completed · Phase 1/Phase 2

Conditions studied: Cancer

In brief

The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.

Key facts

Study ID

NCT00309049

Run by

R-Pharm

People needed

30

Starts

2006-04-01

Expected to finish

2007-05-01

Last updated by the study team

2017-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG status of 0-2.

You may not qualify if…

• Unable to swallow pills.
• Current or recent GI disease or GI surgery.
• Brain mets.
• Severe nerve damage.
• ANC <1,500/mm3
• Platelets <125K.
• Bilirubin >=1.5 times the IULN.
• ALT/AST >=1.5 times the IULN.
• Creatine >1.5 times the IULN.
• Prior treatment with Ixabepilone.
• Strong use of CYPP450 drugs.

Where it is running

• Local Institution — Washington D.C., District of Columbia, United States
• Local Institution — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.